Camrelizumab plus famitinib for advanced or metastatic urothelial carcinoma after platinum-based therapy: data from a multicohort phase 2 study

por Qu, Yuan-Yuan, Sun, Zhongquan, Han, Weiqing, Zou, Qing, Xing, Nianzeng, Luo, Hong, Zhang, Xuepei, He, Chaohong, Bian, Xiao-Jie, Cai, Jinling, Chen, Chunxia, Wang, Quanren, Ye, Ding-Wei
Publicado 2022